DRS114861_1_br_backup

Fasenra Injection

Therapeutic Class: RESPIRATORY
Manufacturer:
Get Quote

Fasenra Injection is a prescription medicine used to treat severe asthma in adults and children aged 6 and older. It is specifically used in people with eosinophilic asthma, a type of asthma characterized by high levels of eosinophils in the blood, which contribute to inflammation in the airways. Fasenra Injection works by targeting and reducing the number of eosinophils (a type of white blood cell) in the body. It blocks a specific protein called IL-5, which is responsible for the growth and survival of eosinophils. By reducing these cells, the medicine helps decrease airway inflammation, leading to fewer asthma attacks and better overall breathing.Fasenra Injection is given as an injection under the skin (subcutaneous injection), typically administered by a doctor or a nurse. The initial dosing schedule involves one injection every 4 weeks for the first three doses, followed by one injection every 8 weeks thereafter.For maximum benefits, stick to your treatment schedule. Missing doses may reduce its effectiveness in controlling asthma symptoms. At the same time, continue using your other asthma medications, such as inhalers, as prescribed by your doctor.The most common side effects of Fasenra Injection are headache and pharyngitis (sore throat). They often go away on their own, however, if they persist or worsen, consult your doctor. Severe allergic reactions, though rare, may occur. Seek immediate medical help if you experience symptoms like rash, swelling, or difficulty breathing.Before starting Fasenra Injection, tell your doctor if you have a history of allergic reactions to benralizumab or any other medication. Avoid receiving live vaccines while on Fasenra Injection, as the medication may weaken your immune response. If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor.

Salt Composition: Benralizumab (30mg)
Strength: Benralizumab (30mg)
Pack Size: pre-filled pen of 1 Injection
Uses: Treatment of Severe Eosinophilic Asthma
Table Header
Salt Composition
Benralizumab (30mg)
Strength
Benralizumab (30mg)
Pack Size
pre-filled pen of 1 Injection
Uses
Treatment of Severe Eosinophilic Asthma
DISCLAIMER
N Chimanlal Enterprises (nicheformulations.com) is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India. Product is supplied for Tenders/ Emergency imports/ Unlicensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials. Product names, logos, brands and other trademarks featured or referred to are the property of their respective Trademark Holders. The information provided here is for Informational purposes only.

Product information is meant for

WholesalersSuppliersExportersDoctorsMOH Tender SuppliesHospitalsBrandCROsComparator SuppliesGenericCooperate SourcingIndividual PatientsIndian Institutional Buyers
Recently Viewed
Categories
predik simbol ini deden berhasil menang besar tanpa modal besarr efisiensi modal tanpa pola bisa jadi naga berkat volatilitas rtp live inii suskes di bet kecil dan besar berkatt pemahaman rng

Select at least 2 products
to compare